SEINE BIO · PEPTIDE PROFILE
XW004
Oral ecnoglutide · an oral peptide formulation
InvestigationalGet to know the name, understand the evidence, and prepare a more informed conversation.
What is XW004?
Sciwind’s oral ecnoglutide program explores a different delivery route from injectable XW003. An early-stage development program is not an approved treatment.
Explore the source
THE FULL READING GUIDE · UPDATED OCTOBER 7, 2026
Inside the science of XW004.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is available only where lawful for the specific substance and patient. Approved finished medicines may also be dispensed by licensed non-compounding pharmacies; this disclaimer does not establish access to any investigational product.
Overview
XW004 is Sciwind’s oral formulation of ecnoglutide, distinct from injectable XW003. Oral peptide development requires both pharmacology and a delivery method that achieves useful exposure. The appeal of a tablet should therefore be considered alongside formulation-specific human data, rather than assuming an injectable molecule’s results carry over unchanged.
Community Use
No exact XW004 page from PeptideDosages or Peptidepedia was verified. The article does not fill that gap with an injectable ecnoglutide or semaglutide protocol. Discussion of an oral development candidate is different from an established consumer regimen, even when an informal source uses a familiar active-ingredient name.
Doses, Durations & Cycles
Published dosing regimens. Product-label and study regimens for education, not instructions for self-treatment. Product, indication and route matter.
| Route / formulation | Dose / reported phases | Frequency | Duration / break | Notes and source |
|---|---|---|---|---|
| Oral tablet | Initial: 2 or 7 mg daily (cohort-dependent) 7, 15 or 30 mg daily | Once daily in the reported cohorts | 15 days (cohorts 1–3); 44 days (cohort 4) Break: No informal off-cycle established by this source | Human study regimen Sciwind Biosciences official release: Positive Results from Phase 1 Clinical Trial of XW004 (23 January 2024) |
Important context: 0.3/0.6/1.2 mg daily is unsupported. Sciwind describes weekly oral development separately; no verified numerical weekly regimen is provided here.
Sources checked October 7, 2026. Educational listing does not establish prescribing approval or availability through Seine Bio.
The table preserves the developer-reported phase 1 cohorts. Sciwind’s January 2024 release describes daily tablet exposures in that early study. Its interest in future weekly oral development does not establish a verified weekly numerical regimen. Injectable amounts cannot be converted into tablet amounts from this page.
Research Findings
The company’s release is a primary developer account of phase 1 findings, not a large confirmatory outcome trial. The current pipeline supplies development context. Early tolerability and exposure findings support further research but cannot answer every question about long-term weight maintenance or uncommon harms.
U.S. Approval & Access
Early clinical development is not FDA approval or permission for ordinary U.S. prescribing. Approval or authorization of an injectable product in another country does not establish the status of this oral formulation. A licensed provider must verify the exact product, jurisdiction and access pathway before discussing actual treatment availability.
What It Does in the Body
XW004 seeks to deliver the GLP-1 agonist ecnoglutide orally. Absorption and formulation influence exposure, so matching the molecule’s name is insufficient. Reliable routine-care onset, peak clinical response and duration after stopping are not established by the early sources. Tablet convenience does not establish a faster or more durable benefit.
Benefits & Reported Experiences
The early company report should be read for its measured endpoints, study length and cohort size, rather than as a promise of lifelong weight control. It can inform what researchers tested. It does not establish that an unofficial oral material matches the formulation or that every patient will achieve the reported experience.
Side Effects & Risks
Human tolerability, gastrointestinal effects and exposure remain formulation-specific questions. A favorable early report is not a complete frequency table for every possible adverse effect. Future studies and longer follow-up matter, particularly before comparing an oral candidate with a marketed medicine supported by substantially more clinical experience.
Delivery Options
The studied route is oral tablet administration. This is a distinct development product, not permission to swallow material intended for injection or to recreate a tablet from raw ingredients. The precise administration conditions belong to the study or future authorized label, which this article does not attempt to reconstruct.
Product Quality & Storage
The identity and delivery technology are essential quality questions. A certificate for ecnoglutide does not demonstrate that a tablet reproduces XW004’s absorption. No verified patient-use storage specification is available here; a lawful program must supply formulation-specific conditions rather than borrowing another GLP-1 product’s refrigeration or shelf-life rules.
Combinations & Interactions
Experimental combinations discussed in a pipeline are not validated personal stacks. XW004 should not be combined with another metabolic medicine on the assumption that receptor overlap or oral delivery makes it harmless. The prescriber or trial team must evaluate concurrent treatment, and this article supplies no combination timing.
Talking With Your Provider
If avoiding injections is your priority, a consultation can explore authorized oral options appropriate to your diagnosis and preferences. XW004 can be discussed as a research direction without making it the only route to progress. A practical care plan considers evidence, tolerability, nutrition and continuity of support as well as delivery convenience.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is available only where lawful for the specific substance and patient. Approved finished medicines may also be dispensed by licensed non-compounding pharmacies; this disclaimer does not establish access to any investigational product.
Questions about what you read?
Explore the research library Create a free account
Educational information only. A free account lets you request review of your care goals. This profile does not establish availability, clinical suitability or access to the named compound.
Explore clinically appropriate options with a licensed provider. Inquiry does not guarantee a prescription, research-program acceptance or access to a particular substance.
Questions worth bringing to your appointment.
- Are there alternatives that address my goal?
- If treatment is appropriate, what monitoring and follow-up would I need?
- Could my health history or current medicines change the risks?
A clinician may recommend a different option—or no medication—after assessing your individual circumstances.
Saved discussion topics 0
Save topics you would like to discuss with your healthcare provider. Saving is an expression of interest, not a treatment request or medical recommendation.
Saved only in this browser, on this device—not in a patient account. Other people using this browser may see your list. Clear it when using a shared device. This list is not sent to our team.
Bring your curiosity. Start a conversation.
Create a free account to request review and manage purchases. Paid membership is optional. Clinical review and authorization still apply where required, and any separate service charges are shown before you agree to pay.
Create a free account ↗This educational information is free to read. Create a free account to request review of your care goals. Neither an account nor paid membership guarantees a prescription, access to the named compound or research enrollment.
Educational profile · U.S. context · October 7, 2026. This page does not provide personalized medical advice, dosing, or injection instructions.
Bring your saved topics to your care team.
Members can select up to five favorites and send a message for review. Your saved list stays in this browser until you choose what to submit.
Choose saved topics for review →